Table 2 Clinical studies involving EZH2 inhibitors in haematological neoplasms

B-NHL, solid advanced tumors

Tazemetostat (oral versus IV)

N/A

1

Recruiting (NCT03010982)

B-NHL and advanced solid tumors

Tazemetostat

Fluconazole, Omeprazole, Repaglinide

1

Active, not recruiting (NCT03028103)

Advanced B-NHL or solid tumors with liver dysfunction

Tazemetostat

N/A

1

Suspended (External information) (NCT03217253)

Relapsed/refractory DLBCL

Tazemetostat

Atezolizumab

1

Active, not recruiting (NCT02220842)

B-NHL, advanced solid tumors

Tazemetostat

Alone or combined with prednisolone

1/2

Recruiting; preliminary results for phase 1 [39] (NCT01897571)

RR FL and DLBCL with or without EZH2 mutation

Tazemetostat

N/A

2

Ongoing; interim results available [40, 41]

RR B-NHL with confirmed EZH2 mutation

Tazemetostat

N/A

2

Not yet recruiting (NCT03456726)

Paediatric patients with NHL, histiocytic disorder or solid tumor with EZH2, SMARCB1 or SMARCA4 mutation

Tazemetostat

N/A

2

Suspended (External information) (NCT03213665)

Patients previously enrolled in Tazemetostat trials

Tazemetostat

Depends on previous trial regimen

2

Recruiting (NCT02875548)

FL, DLBCL, resistant prostate cancer, RR small cell lung carcinoma

PF-06821497

N/A

1

Recruiting (NCT03460977)

B-cell lymphomas

CPI-1205

N/A

1

Active, not recruiting (NCT02395601)

Advanced DLBCL and other malignancies

MAK683

N/A

1/2

Recruiting (NCT02900651)